home of the INTERNATIONAL ATHEROSCLEROSIS SOCIETY
 |  |  | |  

IAS Prevention Guideline plus relevant cardiovascular guidelines from other organizations
Previous and future meetings sponsored by the IAS, the IAS member societies, or relevant affiliated organizations
Current and prior publications that have been sponsored by the IAS, including previous IAS newsletters
Distinguished Fellows of the IAS
Slides available through the IAS, Lorenzini Foundation, and other sites.
IAS monthly newsletter sent by email to all IAS members
Monthly summary of the key literature	in the atherosclerosis field provided each month to all IAS members.
The IAS offers fellowships to young investigators to study in major laboratories
Important websites related to atherosclerosis and related diseases
Computer based algorithms for 10-year risk assessment for cardiovascular disease.
Organizations affiliated with the IAS.


IAS Statin Publication
Update Service


The International Atherosclerosis Society is very pleased to announce an exciting new and informative Newsletter for its membership: The IAS Statin Newsletter. The IAS will begin this month providing curated update on all publications involving statins as identified in PubMed.
For the Issues, click here

ISA 2018 Toronto, Canada

June 9-12, 2018

XVIII International Symposium on
Atherosclerosis
Toronto, Canada

Fellowship Awards
Winners 2016


Blake Cochran
Sydney, Australia


Ingo Hilgendorf
Frieburg, Germany


Yosdel Soto
Havana, Cuba


Winner Reports
Winner 2015 - Hagit Hochner
Winner 2014 - Amanda Foks
Winner 2014 - Nordin Hanssen
Winner 2014 - Marco Busnelli

last updated: May 19, 2017 

ATTENTION! To access some of the content on athero.org you must be a registered user and you must log on.
You can use the interface on the right side of this page to either log on or to register.
  From the IAS President's Desk

Exciting results of the effects of inhibiting PCSK9 on the risk of having a cardiovascular event were presented at the recent meeting of the American College of Cardiology (ACC) held in March 2017 in Washington, DC

The FOURIER trial was the first trial to investigate the cardiovascular benefits and safety of evolocumab, a monoclonal antibody that inhibits the action of PCSK9 in plasma in an effect that increases the number of cell surface LDL receptors and thus lowers the level of LDL cholesterol in plasma. The study was conducted in more than 27,000 people who remained at high risk despite taking effective doses of statins.....

Read more


  IAS FH Activities

IAS SEVERE FH PANEL

IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”

The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.

To download the full text, which is open access, please link to and register at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30041-9/fulltext (Published online May 27, 2016). For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.


Other FH activities


LAUNCH E-LEARNING

Improving management through genetic testing for Familial Hypercholesterolaemia (FH)

This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).
On completion of this e-learning you will have a better understanding of:

  • Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
  • How and why to use genetic testing
  • How to interpret results
  • How to use cascade screening to identify related individuals at risk
You can view the e-learning at http://www.cor2ed.com


FIRST DYSLIPIDEMIA and FH CLINIC in IRAQ

The establishment of the first dyslipidemia and FH clinic in Iraq by Dr. Mutaz Al-Sabah – a research, diagnostic and therapeutic center at the Al-Diwaniyah teaching hospital which will ultimately separate the FH clinic in the future as an independent center dealing with familial lipid disorders. Dr. Al-Sabah has also attended the first IAS-OSLA course on Lipid Metabolism and Cardiovascular Risk held in Muscat-Oman in February 2015 and has been a very active member of the IAS-OSLA Community since then.

Link to event photos

The SAFEHEART Registry

Risk factors for atherosclerotic cardiovascular disease (ASCVD) are variable among patients with Familial Hypercholesterolaemia (FH). SAFEHEART is a multicentre, nationwide, long-term prospective contemporary cohort study of a molecularly defined FH population with or without previous ASCVD. A robust risk prediction equation (SAFEHEART-RE) has been developed using this unique cohort that shows that the risk of incident ASCVD may be estimated in FH patients using clinical and laboratory parameters including age, gender, history of ASCVD, blood pressure, body mass index, smoking, and plasma LDL-C and lipoprotein (a) levels. The Harrell's C index for this model was 0.85.
This information will allow more accurate ASCVD risk prediction in FH and will potentially increase the efficiency of care and use of newer lipid lowering therapies. The SAFEHEART-RE is an accurate tool to implement these predictors in daily clinical practice.

You can view it here


  IAS - OSLA Collaboration in the MENA Region

The International Atherosclerosis Society (IAS) and the Oman Society of Lipid and Atherosclerosis (OSLA) are happy to make available to our readers some important documents related to the 3rd IAS – OSLA Course on Lipid Metabolism and Cardiovascular Risk which was held in Muscat, Oman (February 25-27, 2017) and co-chaired by Profs. Yuji Matsuzawa and Philip Barter of the International Atherosclerosis Society and Dr. Khalid Al-Rasadi, President of the Oman Society of Lipid and Atherosclerosis.

The 4th IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk will be held February, 2018.


  IAS Commentaries

  Meeting and Educational Activity Highlights
To view all highlights, please click here

  Acknowledgements
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission:
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, OSLA - Oman Society of Lipids and Atherosclerosis, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.,Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College


Disclaimer - Cookie policy
This site is optimised for a min. 1024 x 768 pixels resolution

REGISTERED USER
USER ID


PASSWORD




Remember my password


Forgot your password?
Click here


First-time user?
Click here


WHO IS IAS

The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science, research and teaching in the field of atherosclerosis and related diseases.

IAS Newsletter Editors & Website Editorial Board

Editor-in-Chief
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta
Milan, Italy

Emanuela Folco
Milan, Italy

Ann Jackson
Houston, TX, USA

Commentary & Newsletter Editor
Yelonda Williams
(Dallas, TX, USA)

Elena Colombo
(Milan, Italy)